Neo Ivy Capital Management’s Tandem Diabetes Care TNDM Stock Holding History

Neo Ivy Capital Management’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-24	Closed	-$1K	–	547
2022 Q2	$1K	Sell	24 -2,256	-99%	-$185K	﹤0.01%	378
2022 Q1	$266K	Buy	2,280 +1,691	+287%	+$197K	0.24%	151
2021 Q4	$89K	Buy	589 +447	+315%	+$60.3K	0.13%	230
2021 Q3	$14K	Buy	+142	New	+$15.6K	0.02%	409
2021 Q2	–	Sell	-595	Closed	-$53K	–	611
2021 Q1	$53K	Buy	+595	New	+$55.3K	0.06%	323
2020 Q3	–	Sell	-142	Closed	-$14K	–	620
2020 Q2	$14K	Buy	+142	New	+$11.3K	0.02%	409
2019 Q4	–	Sell	-5,153	Closed	-$373K	–	392
2019 Q3	$373K	Buy	+5,153	New	+$329K	0.24%	170
2019 Q2	–	Sell	-2,462	Closed	-$156K	–	403
2019 Q1	$156K	Buy	+2,462	New	+$129K	0.09%	212

Other funds holding TNDM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Neo Ivy Capital Management's TNDM Position: Q3 2022 in Review

Neo Ivy Capital Management sold out of Tandem Diabetes Care (TNDM) in Q3 2022, closing a stake of 24 shares — an estimated $1K sold.

Neo Ivy Capital Management first reported a position in TNDM in Q1 2019 and held it in 8 quarters. The position peaked at $373K in Q3 2019. 299 funds tracked by Wall St. Rank hold TNDM as of Q3 2022.

Neo Ivy Capital Management reported no remaining Tandem Diabetes Care position as of Q3 2022 after selling out during the quarter.
Neo Ivy Capital Management sold 24 Tandem Diabetes Care shares in Q3 2022, an estimated $1K.
Neo Ivy Capital Management first reported a position in Tandem Diabetes Care in Q1 2019 and held it in 8 quarters.
Neo Ivy Capital Management's Tandem Diabetes Care position peaked at $373K in Q3 2019.
299 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q3 2022.

Based on Neo Ivy Capital Management's 13F filing for Q3 2022, filed 16 Nov 2022.